SC 13G/A 1 c11710sc13gza.htm SCHEDULE 13G/A Schedule 13G/A

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934
(Amendment No. 1)*

SINOVAC BIOTECH LTD.
(Name of Issuer)
Common Shares
(Title of Class of Securities)
P8696W104
(CUSIP Number)
December 31, 2010
(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     o Rule 13d-1(b)

     þ Rule 13d-1(c)

     o Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 
 


 

                     
CUSIP No.
 
P8696W104 
 

 

           
1   NAMES OF REPORTING PERSONS

SAIF Partners IV L.P.
     
     
2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

  (a)   o
  (b)   þ
     
3   SEC USE ONLY
   
   
     
4   CITIZENSHIP OR PLACE OF ORGANIZATION
   
  Cayman Islands
       
  5   SOLE VOTING POWER
     
NUMBER OF   3,724,215 common shares
       
SHARES 6   SHARED VOTING POWER
BENEFICIALLY    
OWNED BY   0
       
EACH 7   SOLE DISPOSITIVE POWER
REPORTING    
PERSON   3,724,215 common shares
       
WITH: 8   SHARED DISPOSITIVE POWER
     
    0
     
9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
   
  3,724,215 common shares
     
10   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
   
  o
     
11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
   
  6.88%
     
12   TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
   
  PN


 

                     
CUSIP No.
 
P8696W104 
 

 

           
1   NAMES OF REPORTING PERSONS

SAIF IV GP, L.P.
     
     
2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

  (a)   o
  (b)   þ
     
3   SEC USE ONLY
   
   
     
4   CITIZENSHIP OR PLACE OF ORGANIZATION
   
  Cayman Islands
       
  5   SOLE VOTING POWER
     
NUMBER OF   3,724,215 common shares
       
SHARES 6   SHARED VOTING POWER
BENEFICIALLY    
OWNED BY   0
       
EACH 7   SOLE DISPOSITIVE POWER
REPORTING    
PERSON   3,724,215 common shares
       
WITH: 8   SHARED DISPOSITIVE POWER
     
    0
     
9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
   
  3,724,215 common shares
     
10   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
   
  o
     
11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
   
  6.88%
     
12   TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
   
  PN


 

                     
CUSIP No.
 
P8696W104 
 

 

           
1   NAMES OF REPORTING PERSONS

SAIF IV GP Capital Ltd.
     
     
2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

  (a)   o
  (b)   þ
     
3   SEC USE ONLY
   
   
     
4   CITIZENSHIP OR PLACE OF ORGANIZATION
   
  Cayman Islands
       
  5   SOLE VOTING POWER
     
NUMBER OF   3,724,215 common shares
       
SHARES 6   SHARED VOTING POWER
BENEFICIALLY    
OWNED BY   0
       
EACH 7   SOLE DISPOSITIVE POWER
REPORTING    
PERSON   3,724,215 common shares
       
WITH: 8   SHARED DISPOSITIVE POWER
     
    0
     
9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
   
  3,724,215 common shares
     
10   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
   
  o
     
11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
   
  6.88%
     
12   TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
   
  CO


 

     
Item 1(a)
  Name of Issuer:
 
   
 
  Sinovac Biotech Ltd. (“Issuer”)
 
   
Item 1(b)
  Address of Issuer’s Principal Executive Offices:
 
   
 
  No. 39 Shangdi Xi Road, Haidian District, Beijing 100085, China
 
   
Item 2(a)
  Name of Person Filing:
 
   
 
  SAIF Partners IV L.P.
SAIF IV GP, L.P.
SAIF IV GP Capital Ltd.
 
   
Item 2(b)
  Address of Principal Business Office or, If None, Residence; Citizenship
 
   
 
  SAIF Partners IV L.P.
c/o Maples Corporate Services Limited
P.O. Box 309, Ugland House
Grand Cayman, KY1-1104
Cayman Islands
 
   
 
  c/o SAIF Advisors Limited
Suite 2516 — 2520, Two Pacific Place,
88 Queensway, Hong Kong
 
   
 
  SAIF IV GP, L.P.
c/o Maples Corporate Services Limited
P.O. Box 309, Ugland House
Grand Cayman, KY1-1104
Cayman Islands
 
   
 
  c/o SAIF Advisors Limited
Suite 2516 — 2520, Two Pacific Place,
88 Queensway, Hong Kong
 
   
 
  SAIF IV GP Capital Ltd.
c/o Maples Corporate Services Limited
P.O. Box 309, Ugland House
Grand Cayman, KY1-1104
Cayman Islands
 
   
 
  c/o SAIF Advisors Limited
Suite 2516 — 2520, Two Pacific Place,
88 Queensway, Hong Kong
 
   
Item 2(c)
  Citizenship
 
   
 
  SAIF Partners IV L.P. — Cayman Islands
SAIF IV GP, L.P. — Cayman Islands
SAIF IV GP Capital Ltd. — Cayman Islands
 
   

 

 


 

     
Item 2(d)
  Title of Class of Securities:
 
   
 
  Common shares, par value US$0.001 per share
 
   
Item 2(e)
  CUSIP Number:
 
   
 
  P8696W104
 
   
Item 3.
  Statement Filed Pursuant to Rule 13d-1(b) or 13d-2(b) or (c):
 
   
 
  Not applicable.
 
   
Item 4.
  Ownership
 
   
 
  The information for each reporting person contained in Items 5-11 of the cover pages is incorporated herein by reference
 
   
 
  SAIF IV GP Capital Ltd. is the sole general partner of SAIF IV GP, L.P., which is the sole general partner of SAIF Partners IV L.P. Andrew Y. Yan is the sole director and shareholder of SAIF IV GP Capital Ltd. Pursuant to Section 13(d) of the Exchange Act, Mr. Yan may be deemed to beneficially own all of the shares held by SAIF Partners IV L.P. in the Issuer. Mr. Yan disclaims such beneficial ownership.
 
   
Item 5.
  Ownership of Five Percent or Less of a Class
 
   
 
  Not applicable.
 
   
Item 6.
  Ownership of More Than Five Percent on Behalf of Another Person
 
   
 
  Not applicable.
 
   
Item 7.
  Identification and Classification of Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person
 
   
 
  Not applicable.
 
   
Item 8.
  Identification and Classification of Members of the Group
 
   
 
  Not applicable.
 
   
Item 9.
  Notice of Dissolution of Group
 
   
 
  Not applicable.
 
   
Item 10.
  Certifications
 
   
 
  Not applicable.

 

 


 

SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. In addition, by signing below, the undersigned agrees that this Schedule 13G may be filed jointly on behalf of each of the Reporting Persons.
Dated: February 10, 2011
         
 
SAIF Partners IV L.P.
 
 
  By:     /s/ Andrew Y. Yan  
  Name:   Andrew Y. Yan    
  Title:   Director of SAIF IV GP Capital Ltd., which is the General Partner of SAIF IV GP, L.P., which is the General Partner of SAIF Partners IV L.P.   
 
 
SAIF IV GP L.P.
 
 
  By:     /s/ Andrew Y. Yan   
  Name:   Andrew Y. Yan    
  Title:   Director of SAIF IV GP Capital Ltd., which is the General Partner of SAIF IV GP, L.P.   
 
 
SAIF IV GP Capital Ltd.
 
 
  By:     /s/ Andrew Y. Yan   
  Name:   Andrew Y. Yan   
  Title:   Director of SAIF IV GP Capital Ltd.   

 

 


 

         
LIST OF EXHIBITS
     
Exhibit No.   Description
A
  Joint Filing Agreement (incorporated by reference to Exhibit A of the initial Schedule 13G filed with the Securities and Exchange Commission on November 15, 2010)